Investors
People are different and so is their cancer, patients should be treated individually.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
Read
Latest News
Dr. Raphael Gruber joins 2cureX as new Medical Director
Read more
Interim Report Q2 2022 released
View previous reports
Interim Report Q3 2022 released
Year-End Report 2022 released
IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.
